Seasonal Affective Disorder |
SAD |
Clinical Trial: Therapies for Treatment-Resistant Panic Disorder Symptoms
This study is currently recruiting patients.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Panic Disorder | Drug: Clonazepam Drug: Sertraline Behavior: Cognitive behavior therapy | Phase IV |
MedlinePlus related topics: Panic Disorder
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: Treatment Refractory Panic Disorder
Secondary Outcomes: Clinical global improvement
Expected Total Enrollment: 145
Study start: March 1999; Expected completion: January 2008
Last follow-up: September 2007; Data entry closure: November 2007
Panic disorder is a serious condition that may cause significant psychological and physical distress. Many patients with panic disorder remain symptomatic despite initial intervention. Unfortunately, little data is available to guide health care providers in "next-step" treatment approaches. This study will evaluate the effectiveness of treatments for individuals with panic disorder that is resistant to initial treatment with SSRIs.
This study will last 24 weeks and will comprise three phases. In Phase 1, participants will receive the SSRI sertraline for 6 weeks. Phase 1 will be used to determine participants'''' resistance to treatment. During Phase 1, participants will begin a medication schedule and symptom diary and will have weekly study visits to assess regimen adherence and any side effects they may be experiencing. In Phase 2, participants will be randomly assigned to 6 weeks of one of two treatments: sertraline at an elevated dose from that given in Phase 1 or a sertraline and placebo regimen. During Phase 2, participants will have 3 study visits. Self-report scales and diary entries will be used to assess panic disorder symptoms and medication side effects. In Phase 3, participants will be randomly assigned to receive either CBT or sertraline and clonazepam for 12 weeks. All participants will have weekly study visits during Phase 3. Questionnaires and self-report scales will be used to assess participants at the end of Phase 3.
Study hypothesis: Combined selective serotonin reuptake inhibitors (SSRIs) and benzodiazepine treatment, increasing the dose of SSRI, and the addition of cognitive behavioral therapy (CBT) each may have benefits for patients with panic disorder who remain symptomatic after initial treatment with SSRIs.
Eligibility
Inclusion Criteria:
- Diagnosis of panic disorder
Exclusion Criteria:
- History of bipolar disorder, schizophrenia, psychosis, or delusional disorders
- Post-traumatic stress disorder diagnosis within 6 months prior to study entry
- Current use of psychotropic medications
- Current use of cognitive behavioral therapy
Location and Contact Information
Massachusetts
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States; Recruiting
Naomi M. Simon, MD, MSc, Principal Investigator
Naomi M. Simon, MD, MSc, Principal Investigator, Massachusetts General Hospital
More Information
Click here for more information about the Center for Anxiety and Traumatic Stress Related Disorders
Record last reviewed: July 2005
Last Updated: July 21, 2005
Record first received: July 8, 2005
ClinicalTrials.gov Identifier: NCT00118417
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-07-26
Resources
- Ask NOAH About: Seasonal Affective DisorderFact Sheet (New York Online Access to Health, The New York Hospital Cornell Medical Center (NOAH))
- ClinicalTrials.gov: Seasonal Affective Disorder (National Institutes of Health)

Not Signed In -

